Oct 19, 2021 10:30am EDT MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21
Oct 05, 2021 10:00am EDT MyMD Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7
Sep 22, 2021 11:00am EDT MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD
Sep 13, 2021 10:00am EDT MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan
Sep 09, 2021 10:15am EDT MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15
Aug 24, 2021 10:17am EDT MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and Asthma
Aug 10, 2021 2:30pm EDT MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases
Aug 10, 2021 10:30am EDT MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine
Aug 05, 2021 10:30am EDT MyMD Pharmaceuticals’ Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study
Jul 27, 2021 9:15am EDT MyMD Pharmaceuticals’ Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and Dermatitis
